Clinical trials of vitamin E

TrialResults-center www.trialresultscenter.org

1 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
vitamin E vs control			
GISSI , 1999 n=5660/5664 follow-up: 3.5y	vitamin E 300mg/d versus no vitamine E	patients with recent (3 months) myocardial infarction	Factorial plan open Italy
PPP , 2001 n=2231/2264 follow-up: 3.6y	vitamin E (300 mg/day) versus no vitamin E	men and women aged 50 years or greater, with at least one of the major recognised cardiovascular risk factors	Factorial plan open Italy
vitamin E vs placebo			
CHAOS , 1996 n=1035/967 follow-up: 1.5y	vitamin E 400-800UI/d (alpha tocopherol) versus identical placebo	patients with angiographically proven coronary atherosclerosis	Parallel groups double-blind UK
SPACE , 2000 n=97/99 follow-up: 1.42 years	vitamin E 800 IU daily versus matching placebo	Haemodialysis patients aged 4075 years with pre-existing cardiovascular disease	Parallel groups double -blind Israel
HOPE , 2000 n=4761/4780 follow-up: 4.5y	vitamin E 400IU/d from natural sources versus matching placebo	women and men 55 years of age or older who were at high risk for cardiovascular events because they had cardiovascular disease or diabetes in addition to one other risk factor.	Factorial plan double-blind Multinational: Canada, USA, Europe, South America
ATBC vitamin E , 1994 n=14564/14569 follow-up: 6.1 median (range 5-8y)	vitamin E (alpha-tocopherol) 50mg/d versus placebo	male smokers 50 to 69 years of age from southwestern Finland	Factorial plan double-blind Southwestern Finland
WACS vitamin E , 2007 [NCT00000541] n=4083/4088 follow-up: 9.4 years	vitamin E (600IU every two days) versus placebo	female health professionals at increased risk (40 years or older with a history of CVD or 3 or more CVD risk factors)	Factorial plan double blind US

continued...

Trial	Treatments	Patients	Trials design and methods
WHS vitamin E , 2005 [NCT00000479] n=19937/19939 follow-up: 10.1 y	vitamin E 600 IU every other day (-tocopherol) versus placebo	apparently healthy US women aged at least 45 years	Factorial plan double-blind US
PHS II vitamin E , 2008 [NCT00270647] n=7315/7326 follow-up: 8 years (mean)	vitamin E 400IU every two days versus placebo	US male physicians aged 50 years or older	double blind US
HOPE renal insufficiency subgroup , 2004 n=499/494 follow-up: 4.5y	vitamin E 400 IU/day, natural versus placebo	patients with either known cardiovascular disease or diabetes and at least one additional coronary risk factor and renal insufficiency (sub group)	Factorial plan double-blind North and South America, Europe
ASAP , 2000 n=260/260 follow-up: 3 years	d-alpha-tocopherol 91 mg (136 IU) twice daily versus placebo	smoking and nonsmoking men and postmenopausal women aged 45-69 years with serum cholesterol >= 5.0 mmol/l	Factorial plan double-blind Finland
ATBC 2nd prev subgroup (vitamin E) , 1998 n=916/879 follow-up: 3.79 y	alpha tocopherol (vitamin E) 50 mg/day versus placebo	patients enroled in the ATBC trial and who had angina pectoris in the Rose chest pain questionnaire at baseline	Factorial plan double-blind Finland
AREDS , 2001 n=2370/2387 follow-up: 6.3 y	daily supplementation of antioxidants (500 mg of vitamin C, 400 IU of vitamin E, and 15 mg of beta carotene) versus placebo	patients with age-related lens opacities and visual acuity loss	Factorial plan double-blind USA
Linxian , 1993 n=14792/14792 follow-up: 5y	-	Apparently healthy Individuals of ages 40-69	

More details and results :

- antioxydants for cardiovascular prevention in all type of patients at http://www.trialresultscenter.org/godirect.asp?q=131
- antioxydants for cardiovascular prevention in patients with renal disease at http://www.trialresultscenter.org/godirect.asp?q=432
- antioxydants for cardiovascular prevention in primary prevention at http://www.trialresultscenter.org/godirect.asp?q=433
- antioxydants for cardiovascular prevention in secondary prevention at http://www.trialresultscenter.org/godirect.asp?q=434

References

GISSI, 1999:

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999 Aug 7;354:447-55 [10465168]

PPP, 2001:

de Gaetano G Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001 Jan 13;357:89-95 [11197445]

CHAOS, 1996:

Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) Lancet 1996 Mar 23;347:781-6 [8622332]

SPACE, 2000:

Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000 Oct 7;356:1213-8 [11072938]

HOPE, 2000:

Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000 Jan 20;342:154-60 [10639540]

Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, Ross C, Arnold A, Sleight P, Probstfield J, Dagenais GR Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005 Mar 16;293:1338-47 [15769967]

ATBC vitamin E, 1994:

The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994 Apr 14;330:1029-35 [8127329]

Kataja-Tuomola MK, Kontto JP, Mnnist S, Albanes D, Virtamo JR Effect of alpha-tocopherol and beta-carotene supplementation on macrovascular complications and total mortality from diabetes: results of the ATBC Study. Ann Med 2010 Apr;42:178-86 [20350251]

Leppl JM, Virtamo J, Fogelholm R, Huttunen JK, Albanes D, Taylor PR, Heinonen OP Controlled trial of alpha-tocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers. Arterioscler Thromb Vasc Biol 2000;20:230-5 [10634823]

WACS vitamin E, 2007:

Cook NR, Albert CM, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, Buring JE, Manson JE A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. Arch Intern Med 2007;167:1610-8 [17698683]

Manson JE, Gaziano JM, Spelsberg A, Ridker PM, Cook NR, Buring JE, Willett WC, Hennekens CH A secondary prevention trial of antioxidant vitamins and cardiovascular disease in women. Rationale, design, and methods. The WACS Research Group. Ann Epidemiol 1995;5:261-9 [8520707]

WHS vitamin E, 2005:

Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:56-65 [15998891] 10.1001/jama.294.1.56

PHS II vitamin E, 2008:

Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson JE, Glynn RJ, Gaziano JM Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA 2008 Nov 12;300:2123-33 [18997197]

HOPE renal insufficiency subgroup, 2004:

Mann JF, Lonn EM, Yi Q, Gerstein HC, Hoogwerf BJ, Pogue J, Bosch J, Dagenais GR, Yusuf S Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. Kidney Int 2004;65:1375-80 [15086477] 10.1111/j.1523-1755.2004.00513.x

ASAP, 2000:

Leppl JM, Virtamo J, Fogelholm R, Huttunen JK, Albanes D, Taylor PR, Heinonen OP Controlled trial of alpha-tocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers. Arterioscler Thromb Vasc Biol 2000;20:230-5 [10634823]

Salonen JT, Nyyssnen K, Salonen R, Lakka HM, Kaikkonen J, Porkkala-Sarataho E, Voutilainen S, Lakka TA, Rissanen T, Leskinen L, Tuomainen TP, Valkonen VP, Ristonmaa U, Poulsen HE Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J Intern Med 2000;248:377-86 [11123502]

Salonen RM, Nyyssnen K, Kaikkonen J, Porkkala-Sarataho E, Voutilainen S, Rissanen TH, Tuomainen TP, Valkonen VP, Ristonmaa U, Lakka HM, Vanharanta M, Salonen JT, Poulsen HE Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. Circulation 2003;107:947-53 [12600905]

ATBC 2nd prev subgroup (vitamin E), 1998:

Rapola JM, Virtamo J, Ripatti S, Haukka JK, Huttunen JK, Albanes D, Taylor PR, Heinonen OP Effects of alpha tocopherol and beta carotene supplements on symptoms, progression, and prognosis of angina pectoris. Heart 1998;79:454-8 [9659191]

Rapola JM, Virtamo J, Ripatti S, Huttunen JK, Albanes D, Taylor PR, Heinonen OP Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997;349:1715-20 [9193380] 10.1016/S0140-6736(97)01234-8

AREDS, 2001:

A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9. Arch Ophthalmol 2001 Oct;119:1439-52 [11594943]

Linxian, 1993:

Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, Yang CS, Zheng SF, Gail M, Li GY Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 1993;85:1483-92 [8360931]

Mark SD, Wang W, Fraumeni JF Jr, Li JY, Taylor PR, Wang GQ, Guo W, Dawsey SM, Li B, Blot WJ Lowered risks of hypertension and cerebrovascular disease after vitamin/mineral supplementation: the Linxian Nutrition Intervention Trial. Am J Epidemiol 1996 Apr 1;143:658-64 [8651227]

Entry terms: vitamin e